NRX Pharmaceuticals
NRXP
33 hedge funds and large institutions have $13.2M invested in NRX Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 1 reducing their positions, and 4 closing their positions.
1,200% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 1
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
65% more call options, than puts
Call options by funds: $470K | Put options by funds: $285K
18% more funds holding
Funds holding: 28 → 33 (+5)
1.08% more ownership
Funds ownership: 17.68% → 18.77% (+1.1%)
7% less capital invested
Capital invested by funds: $14.2M → $13.2M (-$924K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGI
B Group Inc
Dallas,
Texas
|
+$6.06M |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$187K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$184K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$159K |
| 5 |
HT
Headlands Technologies
Chicago,
Illinois
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$8.25M |
| 2 |
Two Sigma Investments
New York
|
-$47.3K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.3K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$8.78K |
| 5 |
Morgan Stanley
New York
|
-$2 |
NRXP Hedge Fund Activity: Q1 2026 in Review
33 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2026, worth a combined $13.2M — down 6.5% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NRXP positions and 4 closed out — a net gain of 7 holders — while 13 added to existing stakes and 1 trimmed.
The largest buyer was B Group Inc, opening a new position worth an estimated $6.06M. The largest seller was Anson Funds Management, exiting entirely with an estimated $8.25M sold.
- 33 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2026, up from 28 in Q4 2025.
- Funds reported $13.2M of NRX Pharmaceuticals stock for Q1 2026, down 6.5% quarter-over-quarter.
- 11 funds opened new NRX Pharmaceuticals positions in Q1 2026 and 4 closed out, a net change of +7 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2026 was B Group Inc, an estimated $6.06M added.
- The largest NRX Pharmaceuticals seller in Q1 2026 was Anson Funds Management, an estimated $8.25M sold.
Based on aggregated 13F filings for Q1 2026.